Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-01

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effects of add-on carotenoid plus anti-oxidant nutritional supplementation to standard anti-vascular endothelial growth factor therapy for subjects with center-involved diabetic macular edema

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research Study in Patients With Persistent Macular Edema

NCT00035906

Diabetes Macular Edema Diabetic Retinopathy +2 more

COMPLETED PHASE2

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

NCT04117022

Diabetes Diabetic Retinopathy

UNKNOWN NA

Laser and Antioxidant Treatment of Diabetic Macular Edema

NCT00055042

Macular Edema Diabetes Mellitus

COMPLETED PHASE1

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519

Diabetic Retinopathy

COMPLETED PHASE3

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

NCT00320814

Diabetic Macular Edema

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetic retinopathy (DR) remains the leading cause of blindness in Americans of working age, and the majority of people with diabetes are expected to develop retinopathy, with as many as 10% developing sight-threatening retinopathy (proliferative retinopathy and/or center-involved macular edema) during their lifetime. Established risk factors for DR and diabetic macular edema (DME) include duration of disease, metabolic control (particularly severity and duration of hyperglycemia and hypertension), early age of diabetes diagnosis, male gender, Black and Hispanic race/ethnicity, and albuminuria (kidney disease). , In particular, DME accounts for the majority of vision loss due to diabetes, with significant impacts on activities of daily living and quality of life. Approximately 30% of patients with diabetes develop DME within twenty years of diagnosis.

Available treatments for DME include laser photocoagulation, intravitreal steroids via injection or sustained release implant and, most importantly, intravitreal injection of inhibitors of vascular endothelial growth factor (anti-VEGF). In a number of clinical trials, serial injections of anti-VEGF agents have demonstrated superiority for both reducing intra-retinal edema and improving/stabilizing visual acuity in patients with DME, and their use has become the recognized standard of care, particularly when DME is at or very near the foveal center (center-involved diabetic macular edema, CI-DME). However, anti-VEGF drugs for DME typically require multiple injections, are expensive, carry small but measurable risk of ocular and potentially systemic complications, and are not universally or adequately effective.

A number of biochemical processes have been elucidated as contributing factors in DME, including disruption of the cellular electron transport chain leading to excess production of mitochondrial reactive oxygen and nitrogen species (ROS and RNS) that drives accumulation of injurious glucose metabolites, with concomitant elevation of inflammatory cytokines, leukostasis, apoptosis (programmed cell death), retinal capillary leakage and release of vasoproliferative factors. More recent evidence has suggested that nutritional supplements may interfere with the pathogenesis of structural and functional abnormalities associated with diabetes and diabetic retinopathy. Specifically, use of a novel, multi-component, orally administered nutritional supplement was shown to improve visual function (contrast sensitivity, color perception, visual field) and serum markers of inflammation (hsCRP) in patients with non-proliferative diabetic retinopathy without affecting blood glucose control in an IRB-approved (Western IRB number 1129944 Olympia, WA) randomized, placebo-controlled clinical trial (The Diabetes Visual Function Supplement Study \[DiVFuSS\]

Hypothesis

Our aim is to test the hypothesis that adjunctive supplementation with the DiVFuSS formula, in addition to conventional anti-VEGF therapy with add-on laser photocoagulation and/or intravitreal steroid as necessary, will result in reduced macular edema, fewer required anti-VEGF injections and better visual acuity in treatment-naïve CI-DME subjects receiving therapy over two years in a retinal specialty clinic. A secondary outcome to be assessed is the percentage of patients requiring add-on laser or steroid treatment over the two years in each of the study groups.

Overview of Study Design

This will be an investigator initiated, single-clinic/two location, double-blinded prospective study of 150 adult subjects with newly diagnosed CI-DME receiving anti-VEGF injections, with add-on laser and/or steroid as required on follow-up examination (Standard Treatment) versus standard treatment plus adjunctive DiVFuSS supplementation in one of two doses (2 softgels per day - Supplement Treatment Group 1; and 4 softgels per day - Supplement Treatment Group 2). Subjects will be identified and enrolled with informed consent from two retinal specialty practice sites in Washington State (Sound Retina; Tacoma, WA and Olympia, WA). Subjects will be randomized to Standard Treatment; Supplement Treatment Group 1, or Supplement Treatment Group 2.

Study Allocation: 150 treatment-naïve subjects with CI-DME Requiring anti-VEGF therapy

Standard Treatment Group (50 participants) with treatment-naive center-involved diabetic macular edema will receive anti-VEGF therapy per specialists' usual protocol, with add-on laser or steroid if necessary (at specialist's discretion); Supplement Treatment Group 1 (50 participants) with treatment-naive center-involved diabetic macular edema will receive Standard Treatment plus two DiVFuSS softgels/day; Supplement Treatment Group 2 (50 participants) with treatment-naive center-involved diabetic macular edema will receive Standard Treatment plus four DiVFuSS softgels/day.

After enrollment by the study Primary Investigator, a single retinal specialist from each site, masked to subjects' supplement status, will deliver all treatments per his/her usual protocol for treatment of CI-DME based on individual examination findings. Supplements will be provided by ZeaVision, LLC of Chesterfield, MO. Subjects will receive detailed, dilated eye examinations with additional customary tests (measurement of visual acuity, spectral domain optical coherence tomography, high-resolution retinal photography) performed and recorded by the masked Primary Investigator at baseline, 3 months, 6 months,12 months, 18 months and 24 months. Follow-up phone calls will be performed monthly between visits to help assure compliance for the Test Supplement Treatment Groups (1 and 2). Wide-field fluorescein angiography (FA) will be performed at baseline, 12 months and 24 months per usual care and results recorded by the Primary Investigator.

Test Supplements

The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Center-involved Diabetic Macular Edema (CI-DME)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This will be an investigator initiated, single-clinic/two location, double-blinded prospective study of 150 adult subjects with newly diagnosed CI-DME receiving anti-VEGF injections, with add-on laser and/or steroid as required on follow-up examination (Standard Treatment) versus standard treatment plus adjunctive DiVFuSS supplementation in one of two doses (2 softgels per day - Supplement Treatment Group 1; and 4 softgels per day - Supplement Treatment Group 2). Subjects will be identified and enrolled with informed consent from two retinal specialty practice sites in Washington State (Sound Retina; Tacoma, WA and Olympia, WA). Subjects will be randomized to Standard Treatment; Supplement Treatment Group 1, or Supplement Treatment Group 2.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

After enrollment by the study Primary Investigator, a single retinal specialist from each site, masked to subjects' supplement status, will deliver all treatments per his/her usual protocol for treatment of CI-DME based on individual examination findings. Supplements and identically-appearing placebo will be provided by ZeaVision, LLC of Chesterfield, MO.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Arm - Standard Treatment

50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration

Group Type PLACEBO_COMPARATOR

canola oil placebo softgels, 2 per day

Intervention Type OTHER

Placebo containing canola oil, 2 softgels per day

Experimental Arm - 2 DiVFuSS formula softgel capsules

50 subjects receiving two DiVFuSS softgels per day

Group Type EXPERIMENTAL

Diabetes Visual Function Study (DiVFuSS) softgels

Intervention Type DIETARY_SUPPLEMENT

The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Experimental Arm - 4 DiVFuSS formula softgel capsules

50 subjects receiving 4 DiVFuss softgels per day

Group Type EXPERIMENTAL

Diabetes Visual Function Study (DiVFuSS) softgels

Intervention Type DIETARY_SUPPLEMENT

The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diabetes Visual Function Study (DiVFuSS) softgels

The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Intervention Type DIETARY_SUPPLEMENT

canola oil placebo softgels, 2 per day

Placebo containing canola oil, 2 softgels per day

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Age \< 18 years, inability to give informed consent, evidence of proliferative diabetic retinopathy, evidence of other serious ocular disease (age-related macular degeneration, glaucoma, significant media opacity), history of previous intraocular surgery, including macular or panretinal photocoagulation (except uncomplicated cataract or keratorefractive surgery more than 6 months prior to enrollment), pregnant and nursing women, known sensitivity to any of the supplement ingredients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No